Question 1

Where is the QIAGEN NV stock traded?

Accepted Answer

The QIAGEN NV stock trades under the ticker QIA.XETRA on the XETRA exchange. ISIN: NL0015002SN0.

Question 2

What does QIAGEN NV do?

Accepted Answer

QIAGEN NV is a company characterized by the following investment thesis:

Question 3

What are the key metrics for QIA.XETRA?

Accepted Answer

Key metrics for QIA.XETRA include valuation (P/E 22.7, P/S 3.9, P/B 2.7), profitability (profit margin 19.49%, ROE 11.93%), and growth (revenue –, earnings –). Market capitalization is 8.12B EUR. These metrics give an overview of the company's financial performance and valuation.

Question 4

How has QIAGEN NV's stock price performed?

Accepted Answer

QIAGEN NV's stock has returned – over 1 year, – over 3 years, and – over 5 years. Performance can vary depending on market conditions and company developments.

Question 5

How is QIA.XETRA valued?

Accepted Answer

QIA.XETRA has the following valuation metrics: P/E Ratio: 22.7, P/S Ratio: 3.9, P/B Ratio: 2.7. These metrics help assess whether the stock is fairly valued compared to its fundamentals.

Question 6

Does QIA.XETRA pay dividends?

Accepted Answer

Yes, QIA.XETRA pays dividends with a dividend yield of 0.9%. Dividends can be an important component of the total return on an investment.

Question 7

What are the key risks when investing in QIA.XETRA?

Accepted Answer

Key risks for QIA.XETRA include: Qiagen operates across molecular diagnostics, sample-preparation consumables, and life-science tools, competing against both large diversified instrument and reagent manufacturers and specialist diagnostics and NGS suppliers. Its public competitors include Thermo Fisher, Illumina, Roche, and Agilent, while smaller private specialists in sample preparation and molecular assays create additional pressure on pricing and innovation. The company faces meaningful risks from its reliance on reagent and consumable sales, potential shifts in regulatory and reimbursement frameworks for diagnostic tests, competition from larger vertically integrated players, and exposure to supply-chain concentration and single-market dependencies.The business relies heavily on recurring revenue from consumables and kits. Customer migration toward alternative workflows or competitive pricing pressure can compress margins substantially [8, 3, 21].Regulatory and reimbursement risk stems from product approvals, shifts in diagnostic reimbursement, or new regulatory requirements that could delay sales or erode demand.Large players like Thermo Fisher, Roche, and Illumina have moved toward vertical integration, bundling instruments, assays, and services together. This consolidation creates competitive pressure on pricing and market share for smaller competitors [8, 3, 21].Supply-chain concentration, manufacturing bottlenecks, and dependence on single markets or customers present material risks. Disruptions in component availability or geographic concentration could meaningfully affect revenue.Investors should consider these risk factors carefully before making an investment decision.

Question 8

Who are the main competitors of QIAGEN NV?

Accepted Answer

QIAGEN NV competes with several listed peers in its sector. QIAGEN competes across molecular diagnostics, sample preparation, and NGS sample-prep markets against both large diversified life-science groups and focused diagnostics specialists. The most significant competitive pressure originates from companies with extensive reagent and instrument portfolios—Thermo Fisher, Roche, Danaher, Abbott—and from NGS and instrument specialists such as Illumina, Bio-Rad, and Agilent. The business faces material risks around product reimbursement and adoption dynamics, technology substitution driven by NGS and point-of-care solutions, regulatory and quality compliance requirements, and supply-chain concentration that can pressure both revenue and margins [8, 3, 21].Thermo Fisher Scientific, Inc. (TMO.NYSE)Roche Holding AG (bearer share) (RO.SIX)Illumina, Inc. (ILMN.NASDAQ)Danaher Corporation (DHR.NYSE)Agilent Technologies, Inc. (A.NYSE)Bio‑Rad Laboratories, Inc. (BIO.NYSE)Abbott Laboratories (ABT.NYSE)These competitors influence pricing power, growth opportunities and relative valuation.

Question 9

When does QIAGEN NV report earnings?

Accepted Answer

QIAGEN NV's next earnings report date is November 4, 2026.

Period	P/E Ratio	P/S Ratio	P/B Ratio	P/CF Ratio
Current	22.6	4.4	2.7	14.1
1Y ago	23.1	4.2	2.5	12.8
3Y ago	27.6	4.7	2.6	17.9
5Y ago	22.6	4.9	3.6	18.3

QIAGEN NV P/E & Valuation

Valuation Metrics

Historical valuation trends

Get More Stock Analyses Like This

Unlock Premium

Full Analysis

Ready for professional stock analysis?

Try for Free

Learn more